Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Yкраїнський (UK)
Przejdź do strony domowej biblioteki Centralna Biblioteka Wojskowa Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaCentralna Biblioteka Wojskowa

Wyszukujesz frazę "Inflammatory bowel diseases" wg kryterium: Temat

  Lista filtrów
Wyrównaj
    Wyświetlanie 1-7 z 7
    Tytuł:
    Activity and kinetic properties of phosphotransacetylase from intestinal sulfate-reducing bacteria
    Autorzy:
    Kushkevych, Ivan
    Powiązania:
    https://bibliotekanauki.pl/articles/1039142.pdf
    Data publikacji:
    2015
    Wydawca:
    Polskie Towarzystwo Biochemiczne
    Tematy:
    sulfate-reducing bacteria
    phosphotransacetylase
    kinetic analysis
    inflammatory bowel diseases
    Opis:
    Phosphotransacetylase activity and the kinetic properties of the enzyme from intestinal sulfate-reducing bacteria Desulfovibrio piger and Desulfomicrobium sp. has never been well-characterized and has not been studied yet. In this paper, the specific activity of phosphotransacetylase and the kinetic properties of the enzyme in cell-free extracts of both D. piger Vib-7 and Desulfomicrobium sp. Rod-9 intestinal bacterial strains were presented at the first time. The microbiological, biochemical, biophysical and statistical methods in this work were used. The optimal temperature and pH for enzyme reaction was determined. Analysis of the kinetic properties of the studied enzyme was carried out. Initial (instantaneous) reaction velocity (V0), maximum amount of the product of reaction (Pmax), the reaction time (half saturation period, τ) and maximum velocity of the phosphotransacetylase reaction (Vmax) were defined. Michaelis constants (Km) of the enzyme reaction (3.36 ± 0.35 mM for D. piger Vib-7, 5.97 ± 0.62 mM for Desulfomicrobium sp. Rod-9) were calculated. The studies of the phosphotransacetylase in the process of dissimilatory sulfate reduction and kinetic properties of this enzyme in intestinal sulfate-reducing bacteria, their production of acetate in detail can be perspective for clarification of their etiological role in the development of the humans and animals bowel diseases. These studies might help in predicting the development of diseases of the gastrointestinal tract, by providing further details on the etiology of bowel diseases which are very important for the clinical diagnosis of these disease types.
    Źródło:
    Acta Biochimica Polonica; 2015, 62, 1; 103-108
    0001-527X
    Pojawia się w:
    Acta Biochimica Polonica
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Assessment of DNA damage profile and oxidative /antioxidative biomarker level in patients with inflammatory bowel disease
    Autorzy:
    Mrowicka, Małgorzata
    Mrowicki, Jerzy
    Mik, Michał
    Dziki, Łukasz
    Dziki, Adam
    Majsterek, Ireneusz
    Powiązania:
    https://bibliotekanauki.pl/articles/1391884.pdf
    Data publikacji:
    2020
    Wydawca:
    Index Copernicus International
    Tematy:
    DNA oxidative damage repair
    inflammatory bowel diseases
    pro/antioxidant status
    Opis:
    Aim: The purpose of this study was to investigate the oxidative DNA damage, pro-antioxidant status in Polish patients with inflammatory bowel disease (IBD). Methods: Oxidative DNA damage was measured by comet assay techniques; nitric oxide (NO) and plasmatic lipid peroxidation (MDA) as oxidative stress were valuated by colometric methods; superoxide dismutase (SOD1), catalase (CAT) and glutathione peroxidase (GPx1) as antioxidative defense were determined by spectrophotometric methods. Results: The level of oxidative DNA damage in IBD patients was significantly higher in relation to controls (P = 0.01). Alike, in control subject as well as in patients with IBD, lymphocytes are characterized by complete repair of DNA damage. A significant decrease of SOD (P = 0.031), CAT (P = 0.006), GPx1 (P = 0.001) activity was seen in IBD patients vs control. MDA (P = 0.001) and NO (P = 0.001) concentrations were significantly increased in IBD patients as compared to healthy subjects. Conclusions: Our results may be due to the induction of DNA repair genes which may occur at the stage of the pathological changes (IBD) that may be caused by excessive oxidative stress. However, the cause of this relationship, and whether it is direct or indirect, remains to be explored.
    Źródło:
    Polish Journal of Surgery; 2020, 92, 5; 8-14
    0032-373X
    2299-2847
    Pojawia się w:
    Polish Journal of Surgery
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    What Is “Inflammatory Bowel Disease” & How Can It Be Treated?
    Autorzy:
    Lustyk, Klaudia
    Sapa, Jacek
    Powiązania:
    https://bibliotekanauki.pl/articles/1034045.pdf
    Data publikacji:
    2013
    Wydawca:
    Zakład Opieki Zdrowotnej Ośrodek Umea Shinoda-Kuracejo
    Tematy:
    Crohn’s disease
    Etiology
    Inflammatory bowel diseases
    Therapy
    Ulcerative colitis
    Opis:
    Ulcerative colitis and Crohn's disease are chronic diseases of the gastrointestinal tract, which are usually grouped together as inflammatory bowel disease (IBD). Despite many researches, the etiology is still unknown, but it is believed that IBD is caused by a combination of genetic and environmental factors that interact with the immunological system. Many people worldwide (around 4 million) suffer from a form IBD and the incidence of Crohn's disease is still increasing. Aminosalicylates, corticosteroids, immunomodulators, biologic medicines reduce the inflammation, relieve symptoms, prevent flare-ups, but new, more effective drugs with smaller amount of side effects are wanted and examined.
    Źródło:
    Medicina Internacia Revuo; 2013, 25, 100; 106- 111
    0465-5435
    Pojawia się w:
    Medicina Internacia Revuo
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Clinical application of monoclonal antibodies in targeted therapy
    Autorzy:
    Superson, Maciej
    (, Katarzyna Szmyt
    Szymańska, Katarzyna
    Walczak, Kamil
    Wnorowski, Jeremi
    Zarębski, Łukasz
    Powiązania:
    https://bibliotekanauki.pl/articles/454777.pdf
    Data publikacji:
    2019
    Wydawca:
    Uniwersytet Rzeszowski. Wydawnictwo Uniwersytetu Rzeszowskiego
    Tematy:
    cancer
    inflammatory bowel diseases Alzheimer’s disease immunotherapy
    targeted therapy
    Opis:
    Introduction. Recently, monoclonal antibodies (mAbs) have become powerful human therapeutics in the diagnosis and treatment of many diseases. Drugs based on mAbs are approved for the treatment of cardiovascular, respiratory, hematology, autoimmunology, and oncology diseases. Aim. To present the current state of knowledge about the application of mAbs in the therapy of various diseases such as cancer, autoimmune and Alzheimer’s diseases. Material and methods. We conducted a thorough review of the scientific literature from the following databases: EBSCO, PubMed, Science Direct, and Springer Link. Results. Currently, the Food and Drug Administration (FDA) has approved more than 50 therapeutic mAbs which are applied in various clinical trials. Action of mAb are based on various mechanisms, including directly targeting the cells, modifying the host response, recognizing and degrading molecules as well as delivering cytotoxic moieties. Conclusion. Despite some limitations including side effects, and therapeutic challenges, monoclonal antibodies are an attractive option for the development of new therapies and molecular drug targets against a wide range of common diseases due to their specificity and flexibility. MAbs are considered as a great hope for medicine, and effective and safe drugs in the treatment of various diseases.y
    Źródło:
    European Journal of Clinical and Experimental Medicine; 2019, 4; 338-346
    2544-2406
    2544-1361
    Pojawia się w:
    European Journal of Clinical and Experimental Medicine
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Inflammatory bowel disease: clinical aspects
    Autorzy:
    Pasternak, Grzegorz
    Aebisher, David
    Filip, Rafał
    Bartusik-Aebisher, Dorota
    Powiązania:
    https://bibliotekanauki.pl/articles/454879.pdf
    Data publikacji:
    2018
    Wydawca:
    Uniwersytet Rzeszowski. Wydawnictwo Uniwersytetu Rzeszowskiego
    Tematy:
    inflammatory bowel diseases Leśniowski-Crohn’s disease ulcerative colitis
    mataloproteinases
    Opis:
    Introduction. Inflammatory bowel disease is a complex disease which arises as a result of an interaction between environmental and genetic factors leading to immunological responses and inflammation in the intestine. Aim. To review medical approaches used in inflammatory bowel disorders. Materials and methods. An analysis of literature regarding inflammatory bowel diseases, Leśniowski-Crohn’s disease, ulcerative colitis and mataloproteinases. Results. Current evidence suggests that patients with inflammatory bowel disease may have an elevated risk of endothelial dysfunction and coronary artery disease. Over the past two decades, great advances have been made in our understanding of the interplay between the inflammatory bowel disease. Conclusions. Inflammatory bowel diseases are increasing in Europe. The diagnosis is usually confirmed by biopsies on colonoscopy
    Źródło:
    European Journal of Clinical and Experimental Medicine; 2018, 4; 341-345
    2544-2406
    2544-1361
    Pojawia się w:
    European Journal of Clinical and Experimental Medicine
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Comparison of fecal pyruvate kinase isoform M2 and calprotectin in assessment of pediatric inflammatory bowel disease severity and activity
    Autorzy:
    Czub, Elzbieta
    Nowak, Jan
    Szaflarska-Poplawska, Anna
    Grzybowska-Chlebowczyk, Urszula
    Landowski, Piotr
    Moczko, Jerzy
    Adamczak, Daria
    Mankowski, Przemyslaw
    Banasiewicz, Tomasz
    Plawski, Andrzej
    Walkowiak, Jaroslaw
    Powiązania:
    https://bibliotekanauki.pl/articles/1039342.pdf
    Data publikacji:
    2014
    Wydawca:
    Polskie Towarzystwo Biochemiczne
    Tematy:
    : pyruvate kinase
    calprotectin
    inflammatory bowel diseases
    ulcerative colitis
    Crohn's disease
    pediatrics
    Opis:
    Aims: Accurate assessment of inflammatory bowel disease (IBD) activity is the cornerstone of effective therapy. Fecal M2 isoform of pyruvate kinase (M2-PK) and fecal calprotectin (FC) are noninvasive markers of mucosal inflammation in IBD. The aim of this study was to compare performance of M2-PK and FC in assessment of pediatric ulcerative colitis (UC) and Crohn's disease (CD) severity and activity. Materials and methods: 121 patients with IBD, including 75 with UC and 46 with CD were recruited. Control group consisted of 35 healthy children (HS). Patients were assigned to groups depending on disease severity and activity. M2-PK and calprotectin concentration were determined in stool samples using ELISA. Areas under receiver operating characteristic curves (AUC) for FC and M2-PK with cut-off level at which M2-PK specificity was matching FC specificity were calculated and compared. Results: Performance of M2-PK at identifying patients with IBD, UC and CD among HS was inferior to FC. The differences in AUC were respectively: -0.10 (95% confidence interval [CI] [-0.13-(-0.06)], p<0.0001), -0.14 (95% CI [-0.19-(-0.09)], p<0.0001) and -0.03 (95% CI [-0.05-(-0.001)], p<0.02). M2-PK was inferior to FC in discriminating patients with mild UC from those with HS (AUC difference -0.23, 95% CI [-0.31-(-0.15)], p<0.0001). Conclusions: FC reflects pediatric IBD severity and activity better than M2-PK. This difference is particularly pronounced when identifying patients with mild UC and UC in remission.
    Źródło:
    Acta Biochimica Polonica; 2014, 61, 1; 99-102
    0001-527X
    Pojawia się w:
    Acta Biochimica Polonica
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    The therapeutic potential of short-chain fatty acids enemas in inflammatory bowel diseases: a systematic review
    Potencjał terapeutyczny krótkołańcuchowych kwasów tłuszczowych podawanych doodbytniczo w nieswoistych chorobach zapalnych jelit: przegląd systematyczny
    Autorzy:
    Kaczmarek, Nina
    Kokot, Marta
    Makarewicz, Aleksandra
    Glapa-Nowak, Aleksandra
    Nowak, Jan K.
    Jamka, Małgorzata
    Walkowiak, Jarosław
    Powiązania:
    https://bibliotekanauki.pl/articles/762653.pdf
    Data publikacji:
    2020-07-21
    Wydawca:
    Polskie Towarzystwo Farmaceutyczne
    Tematy:
    choroba Leśniowskiego-Crohna
    nieswoiste choroby zapalne jelit
    krótkołańcuchowe kwasy tłuszczowe
    wrzodziejące zapalenie jelita grubego
    roztwór doodbytniczy
    inflammatory bowel diseases
    Crohn’s disease
    ulcerative colitis
    enema
    short-chain fatty acid
    Opis:
    Sugeruje się, że krótkołańcuchowe kwasy tłuszczowe (SCFA) mogą redukować nasilenie objawów klinicznych, poprawiać wyniki badania endoskopowego i histopatologicznego u pacjentów z nieswoistymi chorobami zapalnymi jelit (IBD). Jednakże, pomimo obiecujących badań in vitro, wyniki badań przeprowadzonych w modelu zwierzęcym oraz randomizowanych badań kontrolowanych (RCT) są niejednoznaczne. Celem tego przeglądu systematycznego była ocena skuteczności SCFA podawanych doodbytniczo u pacjentów z IBD. Wyszukiwanie elektroniczne przeprowadzono w następujących bazach danych: PubMed, Scopus, Web of Science i Cochrane. Kryteria włączenia badań oryginalnych do przeglądu systematycznego obejmowały: 1) rodzaj badań: równoległe lub krzyżowe RCT; 2) język: artykuły w języku angielskim; 3) rodzaj interwencji: SCFA podawane doodbytniczo; 4) populacja badana: pacjenci z wrzodziejącym zapaleniem jelita grubego lub chorobą Leśniowskiego-Crohna, niezależnie od płci, wieku, pochodzenia etnicznego, lokalizacji badania i wielkości próby. Jako punkty końcowe przyjęto wpływ podaży SCFA na wskaźnik aktywności choroby (DAI) oraz wyniki badań endoskopowych i histopatologicznych. Do analizy zakwalifikowano 4 badania obejmujące łącznie 187 pacjentów z IBD. W 2 badaniach oceniano wpływ SCFA na DAI, w 4 badaniach – na wyniki badania endoskopowego i histopatologicznego. Nie stwierdzono istotnych różnic pomiędzy grupą interwencyjną a grupą kontrolną w zakresie wpływu na jakikolwiek analizowany parametr. W 2 badaniach wykazano istotny spadek DAI po okresie interwencji, zarówno w grupie SCFA, jak i w grupie kontrolnej. Podobnie, w 4 badaniach odnotowano statystycznie istotne różnice między wynikami endoskopowymi przed i po interwencji w grupie SCFA. Jednakże, w 3 badaniach podobny efekt zaobserwowano w grupie kontrolnej. Poza tym, w 3 badaniach nie zaobserwowano wpływu SCFA na wyniki histopatologiczne. Podsumowując, brak jest dowodów na skuteczność SCFA podawanych doodbytniczo u pacjentów z IBD.
    It has been suggested that short-chain fatty acid (SCFA) enemas might improve clinical, endoscopic and histological scores in patients with inflammatory bowel disease. However, despite the promising results of in vitro studies, the findings of animal studies and randomised controlled trials are inconclusive. Therefore, this review aimed to assess the efficacy of SCFA enemas in patients with inflammatory bowel diseases. Electronic searches were performed in PubMed, Scopus, Web of Science and Cochrane databases. Original studies were included in this systematic review if they met the following inclusion criteria: 1) types of studies: parallel or crossover randomised controlled trials; 2) language: articles published in English; 3) types of interventions: SCFA enemas; 4) population: studies conducted in subjects with ulcerative colitis or Crohn’s disease of either gender and any age and without restrictions based on the ethnicity of study participants, location of study or sample size. The outcomes included the effect of SCFA enemas on disease activity index (DAI), endoscopic and histological scores. In total, four studies enrolling 187 patients with inflammatory bowel diseases were included in this systematic review. Two studies assessed the effect of SCFA enemas on DAI. Four studies evaluated the effect of SCFA therapy on the endoscopic score and the histological score. There were no significant differences between the SCFA groups and the control groups regarding the impact on any analysed parameter. Two studies demonstrated a statistically significant decrease in DAI after the intervention period, both in the SCFA groups and the control groups. Similarly, statistically significant differences between pre- and post-intervention endoscopic scores in the SCFA groups were reported in four studies. However, in three studies, a similar effect was demonstrated in the control groups. Besides, in three studies no effect of SCFA enemas on the histological score was observed. In conclusion, there is no evidence for the effectiveness of SCFA enemas in patients with inflammatory bowel diseases.
    Źródło:
    Farmacja Polska; 2020, 76, 5; 297-304
    0014-8261
    2544-8552
    Pojawia się w:
    Farmacja Polska
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
      Wyświetlanie 1-7 z 7

      Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies